Cover Image
市場調查報告書

傷口縫合產品:開發平台分析

Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 328677
出版日期 內容資訊 英文 235 Pages
訂單完成後即時交付
價格
Back to Top
傷口縫合產品:開發平台分析 Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年10月01日 內容資訊: 英文 235 Pages
簡介

本報告提供全球各國的企業、醫療機關等正在開發的傷口縫合產品 (傷口縫合設備) 的開發中產品資訊相關分析、臨床實驗/產品開發的整體進展,及各階段、各地區、各領域的詳細趨勢、各企業、各產品的詳細資訊 (臨床實驗的進展階段、開始/結束時期、認證預測等)、近來的開發、資本交易的動向等資料,為您概述為以下內容。

目錄

  • 簡介
    • 傷口縫合產品概要
  • 開發中的產品
    • 開發中產品:各開發階段
    • 開發中產品:各市場區隔
    • 開發中產品:各地區
    • 開發中產品:各法規途徑
    • 開發中產品:各認證時期 (估計)
    • 開發中產品:進行中的臨床實驗
  • 傷口縫合產品:正在開發的開發中產品 (各企業)
    • 傷口縫合產品的開發企業:開發中產品 (各開發階段)
    • 傷口縫合產品:各開發階段的開發中產品
  • 傷口縫合產品的開發企業、產品概要
    • 開發中產品/進行中的臨床實驗概要
  • 3-D Matrix Europe SAS
  • three、D、矩陣
  • Advanced Medical Solutions Group plc
  • Anika Therapeutics, Inc.
  • Arch Therapeutics Inc.
  • Arsenal Medical, Inc.
  • Baxter International Inc.
  • Bergen Medical Products, Inc.
  • Beth Israel Deaconess Medical Center, Inc.
  • Boston Scientific Corporation
  • Boston University
  • C. R. Bard, Inc.
  • Cellphire, Inc.
  • Clemson University
  • Cohera Medical, Inc.
  • Cook Medical Incorporated
  • Covalon Technologies Ltd.
  • CryoLife, Inc.
  • Emory University
  • Endomedix Incorporated
  • Entegrion, Inc.
  • Floralis S.A.S.
  • Gamma Therapeutics, Inc.
  • Gecko Biomedical
  • Grifols, S.A.
  • Haemostatix Ltd
  • Hemostasis, LLC
  • HyperBranch Medical Technology, Inc.
  • InVivo Therapeutics Corporation
  • IonMed Ltd.
  • Johns Hopkins University
  • KeraNetics, LLC
  • Kitotech Medical, Inc.
  • Kuros Biosurgery AG
  • Laser Tissue Welding, Inc.
  • LifeBond Ltd.
  • Medical Adhesive Revolution GmbH
  • Medisse BV
  • Medtronic plc
  • OptMed, Inc.
  • Remedium Technologies Inc.
  • Resultados y Calidad del Sistema Sanitario Publico de Andalucia
  • Rice University
  • Samyang Biopharmaceuticals Corporation
  • Sea Run Holdings Inc.
  • Sealantis Ltd.
  • St Teresa Medical, Inc.
  • Suneris Technologies, Inc.
  • TEIJIN FIBERS製藥
  • The Medicines Company
  • University of Akron
  • VitaThreads, LLC
  • Vivostat A/S
  • Wound Management Technologies, Inc.
  • Xcede Technologies, Inc.
  • 目前的趨勢 (共106件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0473EPD

GlobalData's Medical Devices sector report, "Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017" provides an overview of Wound Closure Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Wound Closure Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Wound Closure Hemostats under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Wound Closure Hemostats and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Wound Closure Hemostats under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Wound Closure Hemostats Overview 12

3 Products under Development 13

  • 3.1 Wound Closure Hemostats - Pipeline Products by Stage of Development 13
  • 3.2 Wound Closure Hemostats - Pipeline Products by Segment 14
  • 3.3 Wound Closure Hemostats - Pipeline Products by Territory 15
  • 3.4 Wound Closure Hemostats - Pipeline Products by Regulatory Path 16
  • 3.5 Wound Closure Hemostats - Pipeline Products by Estimated Approval Date 17
  • 3.6 Wound Closure Hemostats - Ongoing Clinical Trials 18

4 Wound Closure Hemostats - Pipeline Products under Development by Companies 19

  • 4.1 Wound Closure Hemostats Companies - Pipeline Products by Stage of Development 19
  • 4.2 Wound Closure Hemostats - Pipeline Products by Stage of Development 21

5 Wound Closure Hemostats Companies and Product Overview 23

  • 5.1 3-D Matrix Ltd Company Overview 23
    • 5.1.1 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.2 Anika Therapeutics Inc Company Overview 28
    • 5.2.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.3 Arch Therapeutics Inc Company Overview 29
    • 5.3.1 Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.4 Argon Medical Devices Inc Company Overview 31
    • 5.4.1 Argon Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.5 Baxter International Inc Company Overview 32
    • 5.5.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.6 Beth Israel Deaconess Medical Center Inc Company Overview 36
    • 5.6.1 Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.7 Biomedica Management Corp Company Overview 37
    • 5.7.1 Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.8 Biom'Up SAS Company Overview 40
    • 5.8.1 Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.9 C. R. Bard Inc Company Overview 43
    • 5.9.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.10 Cellphire Inc Company Overview 45
    • 5.10.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.11 Ceramicos Para Aplicacoes Medicas Lda Company Overview 47
    • 5.11.1 Ceramicos Para Aplicacoes Medicas Lda Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.12 Columbia University Company Overview 48
    • 5.12.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.13 Covalent Medical, Inc. (Inactive) Company Overview 49
    • 5.13.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.14 Covalon Technologies Ltd Company Overview 50
    • 5.14.1 Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.15 Cresilon Inc Company Overview 52
    • 5.15.1 Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.16 CryoLife Inc Company Overview 54
    • 5.16.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.17 Endomedix Incorporated Company Overview 57
    • 5.17.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.18 Entegrion Inc Company Overview 59
    • 5.18.1 Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.19 Ethicon US LLC Company Overview 60
    • 5.19.1 Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.20 Gamma Therapeutics Inc Company Overview 63
    • 5.20.1 Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.21 gel-e Inc Company Overview 64
    • 5.21.1 gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.22 Haemostatix Ltd Company Overview 66
    • 5.22.1 Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.23 Hemostasis LLC Company Overview 70
    • 5.23.1 Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.24 KeraNetics, LLC Company Overview 72
    • 5.24.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.25 LifeBond Ltd Company Overview 73
    • 5.25.1 LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.26 Resorba GmbH Company Overview 76
    • 5.26.1 Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 76
  • 5.27 Rice University Company Overview 81
    • 5.27.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 81
  • 5.28 Samyang Biopharmaceuticals Corp Company Overview 82
    • 5.28.1 Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 82
  • 5.29 Sanofi Company Overview 83
    • 5.29.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 83
  • 5.30 Sea Run Holdings Inc Company Overview 85
    • 5.30.1 Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 85
  • 5.31 St Teresa Medical Inc Company Overview 86
    • 5.31.1 St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 86
  • 5.32 The Medicines Company Company Overview 88
    • 5.32.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88
  • 5.33 Therus Corporation Company Overview 89
    • 5.33.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 89
  • 5.34 Thrombotargets Corp Company Overview 90
    • 5.34.1 Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 90
  • 5.35 United Health Products, Inc. Company Overview 92
    • 5.35.1 United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 92
  • 5.36 University of Grenoble Alpes Company Overview 95
    • 5.36.1 University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 95
  • 5.37 Virginia Commonwealth University Company Overview 96
    • 5.37.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 96
  • 5.38 Wound Management Technologies Inc Company Overview 97
    • 5.38.1 Wound Management Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 97
  • 5.39 Xcede Technologies Inc Company Overview 98
    • 5.39.1 Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 98

6 Wound Closure Hemostats - Recent Developments 101

  • 6.1 Sep 13, 2017: Advanced Medical Solutions: Interim Results for the six months ended 30 June 2017 101
  • 6.2 Sep 13, 2017: gel-e Expands Core Team with Regulatory, Manufacturing and Financial Talent 101
  • 6.3 Sep 12, 2017: Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5 for Subchronic Systemic Toxicity 102
  • 6.4 Sep 07, 2017: St. Teresa Medical Announces First Commercial Use of SURGICLOT in Auckland, New Zealand 102
  • 6.5 Aug 28, 2017: Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs 103
  • 6.6 Aug 22, 2017: United Health Products Reports Second Quarter 2017 Results 104
  • 6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 104
  • 6.8 Aug 21, 2017: Covalon Releases Third Quarter Financial Results 107
  • 6.9 Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 107
  • 6.10 Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker 110
  • 6.11 Aug 02, 2017: United Health Products Reports Profitable First Quarter ended March 31, 2017 110
  • 6.12 Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd 111
  • 6.13 Jul 31, 2017: Advanced Medical Solutions Group Reports H1 2016 Results 111
  • 6.14 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 111
  • 6.15 Jul 31, 2017: Dr. Joachim Schulz joins the Management Board of B. Braun Melsungen 118
  • 6.16 Jul 28, 2017: Indonesian Minister of Health Launches New German Pharmaceutical Factory in Karawang 119
  • 6.17 Jul 27, 2017: Stryker reports second quarter 2017 results 119
  • 6.18 Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 120
  • 6.19 Jul 26, 2017: Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020 121
  • 6.20 Jul 26, 2017: Merit Medical Reports Record Revenue and Non-GAAP Net Income for Second Quarter 2017, Raises 2017 Guidance and Gives Preliminary 2018-2019 Guidance 123
  • 6.21 Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 124
  • 6.22 Jul 25, 2017: Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5 Topical Gel 125
  • 6.23 Jul 24, 2017: Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat 126
  • 6.24 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results 127
  • 6.25 Jul 20, 2017: Wound Management Technologies Announces Q2 2017 Sales Up 15% over Q2 2016 and All Amortized Debt Retired in the Second Quarter 128
  • 6.26 Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results 128
  • 6.27 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 130
  • 6.28 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 130
  • 6.29 Jun 21, 2017: PeproStat Phase IIb study passes recruitment mid-point ahead of schedule - Top line results brought forward to Q4 2017 132
  • 6.30 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund 133
  • 6.31 Jun 06, 2017: Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017 133
  • 6.32 Jun 06, 2017: Ethicon Announces FDA Approval For SURGICEL Powder Absorbable Hemostat 134
  • 6.33 Jun 06, 2017: Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017 135
  • 6.34 May 29, 2017: Covalon Releases Second Quarter Financial Results 135
  • 6.35 May 26, 2017: Merit Medical Announces Appointment of New Director 136
  • 6.36 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 136
  • 6.37 May 17, 2017: Wound Management Issues 2017 10Q and Hires New Strategic Marketing Director 139
  • 6.38 May 10, 2017: The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures 140
  • 6.39 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 141
  • 6.40 May 03, 2017: Covalon to Exhibit at the 2017 European Wound Management Association's Annual Conference 141
  • 6.41 Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 142
  • 6.42 Apr 28, 2017: Advanced Medical Solutions Group Reports 2016 Financial Results 149
  • 6.43 Apr 27, 2017: Merit Medical Reports Results for First Quarter of 2017 149
  • 6.44 Apr 27, 2017: Q1 2017 Sales Up 32% Over Q1 2016, for Wound Management Technologies 150
  • 6.45 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 150
  • 6.46 Apr 26, 2017: CryoLife Reports First Quarter 2017 Financial Results 152
  • 6.47 Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 153
  • 6.48 Apr 25, 2017: Stryker reports first quarter 2017 results 154
  • 6.49 Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 155
  • 6.50 Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 157
  • 6.51 Apr 18, 2017: United Health Products to file late 2016 audited year end 159
  • 6.52 Apr 16, 2017: Establishment of Lohmann & Rauscher Tunisie s.a.r.l. 159
  • 6.53 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board 159
  • 6.54 Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 160
  • 6.55 Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 160
  • 6.56 Apr 11, 2017: Z-Medica Products Approved For Use In Brazil 161
  • 6.57 Apr 05, 2017: MPP Group Announces Launch Of Dextatic Advanced Wound Care Dressing 162
  • 6.58 Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 162
  • 6.59 Apr 03, 2017: Baxter Unveils Design Enhancement to FLOSEAL Hemostatic Agent at AORN Meeting 163
  • 6.60 Apr 03, 2017: Baxter Unveils Design Enhancement to TISSEEL Hemostatic Agent at AORN Meeting 163
  • 6.61 Mar 31, 2017: B. Braun continues its sales and earnings growth 164
  • 6.62 Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 166
  • 6.63 Mar 21, 2017: SeeThruEquity Issues Report on United Health Products 166
  • 6.64 Mar 14, 2017: New Data Indicates Use of Baxter's FLOSEAL in Cardiac and Spinal Surgeries May Be Associated with Lower Hospital Costs 168
  • 6.65 Mar 14, 2017: Advanced Medical Solutions Group: Unaudited preliminary Results for the year ended 31 December 2016 169
  • 6.66 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 169
  • 6.67 Mar 08, 2017: Wound Management announces appointment of John Siedhoff as Chairman 170
  • 6.68 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 171
  • 6.69 Mar 02, 2017: Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 171
  • 6.70 Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 172
  • 6.71 Feb 22, 2017: Change in the B. Braun Management Board 174
  • 6.72 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 174
  • 6.73 Feb 21, 2017: Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2016 177
  • 6.74 Feb 16, 2017: Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5 178
  • 6.75 Feb 15, 2017: CryoLife Reports Fourth Quarter and Full Year 2016 Financial Results 178
  • 6.76 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 179
  • 6.77 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 180
  • 6.78 Feb 14, 2017: Wound Management Technologies Announces Record Quarterly and Annual Sales Ending December 31, 2016 - Up 147% over Q4 2015, and 63% over 2015 181
  • 6.79 Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 182
  • 6.80 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 190
  • 6.81 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 191
  • 6.82 Feb 02, 2017: Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics 191
  • 6.83 Feb 02, 2017: Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics 192
  • 6.84 Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 193
  • 6.85 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 194
  • 6.86 Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 196
  • 6.87 Jan 30, 2017: Covalon Posts Record First Quarter Financial Results 196
  • 6.88 Jan 24, 2017: Stryker reports 2016 results and 2017 outlook 197
  • 6.89 Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 199
  • 6.90 Jan 10, 2017: Stryker provides 2016 preliminary net sales results 201
  • 6.91 Jan 09, 2017: Johnson & Johnson Medical Devices Companies Launch CareAdvantage, a Suite of Holistic, Insights-Driven Capabilities to Help U.S. Health Systems Navigate Value-Based Care 202
  • 6.92 Jan 03, 2017: Covalon CEO Provides Update on Anticipated Fiscal 2017 Financial Growth 203
  • 6.93 Dec 08, 2016: Wound Management Technologies Welcomes J. Michael Carmena as its New CFO 205
  • 6.94 Dec 07, 2016: Biom'up receives CE Mark Approval for HEMOBLAST Bellows, the first active hemostatic powder for management of mild to moderate intra-operative bleedings 205
  • 6.95 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 206
  • 6.96 Nov 18, 2016: Dynasil and Cook Biotech Join Together to Advance Xcede Technologies Patch through First in Human Trials 209
  • 6.97 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 210
  • 6.98 Nov 03, 2016: ImageIQ Selected as Imaging CRO for CryoLife's PerClot Intraoperative Hemostasis Pivotal Clinical Trial 210
  • 6.99 Nov 03, 2016: ImageIQ Selected as Imaging CRO for CryoLife's PerClot Intraoperative Hemostasis Pivotal Clinical Trial 211
  • 6.100 Nov 01, 2016: Wound Management Technologies Reports Preliminary Financial Results For Q3 2016 Sales Up 56% over Q3 2015, and 2016 YTD Sales Up 41% over 2015 YTD Sales 211
  • 6.101 Oct 31, 2016: Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study 211
  • 6.102 Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results 213
  • 6.103 Oct 27, 2016: Stryker reports third quarter 2016 results 220
  • 6.104 Oct 26, 2016: CryoLife Reports Third Quarter 2016 Financial Results 221
  • 6.105 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 222
  • 6.106 Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016 223
  • 6.107 Oct 26, 2016: The Medicines Company Reports Third-Quarter 2016 Financial Results 223
  • 6.108 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 225
  • 6.109 Oct 25, 2016: James W. Bullock Joins CryoLife Board of Directors 226
  • 6.110 Oct 24, 2016: Vascular Solutions Reports Third Quarter Results 226
  • 6.111 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 229
  • 6.112 Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare 231

7 Appendix 232

  • 7.1 Methodology 232
  • 7.2 About GlobalData 235
  • 7.3 Contact Us 235
  • 7.4 Disclaimer 235

List of Tables

1.1 List of Tables

  • Table 1: Wound Closure Hemostats - Pipeline Products by Stage of Development 13
  • Table 2: Wound Closure Hemostats - Pipeline Products by Segment 14
  • Table 3: Wound Closure Hemostats - Pipeline Products by Territory 15
  • Table 4: Wound Closure Hemostats - Pipeline Products by Regulatory Path 16
  • Table 5: Wound Closure Hemostats - Pipeline Products by Estimated Approval Date 17
  • Table 6: Wound Closure Hemostats - Ongoing Clinical Trials 18
  • Table 7: Hemostats Companies - Pipeline Products by Stage of Development 19
  • Table 8: Hemostats - Pipeline Products by Stage of Development 21
  • Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 10: PuraStat Hemostat - Product Status 24
  • Table 11: PuraStat Hemostat - Product Description 24
  • Table 12: TDM-511 - Product Status 25
  • Table 13: TDM-511 - Product Description 25
  • Table 14: 3-D Matrix Ltd - Ongoing Clinical Trials Overview 26
  • Table 15: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery 27
  • Table 16: PuraStat Hemostat - Randomized Controlled Trial Comparing Purastat to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection 27
  • Table 17: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 18: Hemostatic Patch - Product Status 28
  • Table 19: Hemostatic Patch - Product Description 28
  • Table 20: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 21: AC5 Surgical Hemostatic Device - Product Status 29
  • Table 22: AC5 Surgical Hemostatic Device - Product Description 29
  • Table 23: AC5 Surgical Hemostatic Device - Internal Use - Product Status 30
  • Table 24: AC5 Surgical Hemostatic Device - Internal Use - Product Description 30
  • Table 25: Argon Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 26: Hemaseel Thrombin Haemostatic Agent - Product Status 31
  • Table 27: Hemaseel Thrombin Haemostatic Agent - Product Description 31
  • Table 28: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 29: Hemopatch - Product Status 32
  • Table 30: Hemopatch - Product Description 32
  • Table 31: Baxter International Inc - Ongoing Clinical Trials Overview 33
  • Table 32: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (more than 5 Days - PAL) 34
  • Table 33: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant 34
  • Table 34: Hemopatch - Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the use of the New Hemostatic Patch Hemopatch in Patients undergoing Surgical Liver Resection 34
  • Table 35: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial 35
  • Table 36: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH 35
  • Table 37: Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 38: Portable Wound Hemostasis System - Product Status 36
  • Table 39: Portable Wound Hemostasis System - Product Description 36
  • Table 40: Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 41: ClotFoam - Product Status 37
  • Table 42: ClotFoam - Product Description 37
  • Table 43: ClotGel - Product Status 38
  • Table 44: ClotGel - Product Description 38
  • Table 45: ClotSpray - Product Status 38
  • Table 46: ClotSpray - Product Description 39
  • Table 47: Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 48: Hemoblast Bellows - Product Status 40
  • Table 49: Hemoblast Bellows - Product Description 40
  • Table 50: Biom'Up SAS - Ongoing Clinical Trials Overview 41
  • Table 51: Hemoblast Bellows - Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of Hemoblast Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries 42
  • Table 52: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 53: New Hemostat 1 - Product Status 43
  • Table 54: New Hemostat 1 - Product Description 43
  • Table 55: New Hemostat 2 - Product Status 44
  • Table 56: New Hemostat 2 - Product Description 44
  • Table 57: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 58: Thromboderm - Product Status 45
  • Table 59: Thromboderm - Product Description 45
  • Table 60: Thrombosomes - Hemostatic Agent - Product Status 46
  • Table 61: Thrombosomes - Hemostatic Agent - Product Description 46
  • Table 62: Ceramicos Para Aplicacoes Medicas Lda Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 63: HemoKi - Product Status 47
  • Table 64: HemoKi - Product Description 47
  • Table 65: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 66: Hemostatic Wound Dressing - Product Status 48
  • Table 67: Hemostatic Wound Dressing - Product Description 48
  • Table 68: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 69: CovaSTAT - Product Status 49
  • Table 70: CovaSTAT - Product Description 49
  • Table 71: Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 72: ColActive THP - Product Status 50
  • Table 73: ColActive THP - Product Description 51
  • Table 74: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status 51
  • Table 75: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description 51
  • Table 76: Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 77: TRAUMAGEL - Product Status 52
  • Table 78: TRAUMAGEL - Product Description 52
  • Table 79: VETIGEL - Product Status 53
  • Table 80: VETIGEL - Product Description 53
  • Table 81: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 82: PerClot - Product Status 54
  • Table 83: PerClot - Product Description 54
  • Table 84: CryoLife Inc - Ongoing Clinical Trials Overview 55
  • Table 85: PerClot - Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot Polysaccharide Hemostatic System 56
  • Table 86: Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 87: Surgical Hemostat - Intracranial Surgery - Product Status 57
  • Table 88: Surgical Hemostat - Intracranial Surgery - Product Description 57
  • Table 89: Topical Hemostat - Product Status 58
  • Table 90: Topical Hemostat - Product Description 58
  • Table 91: Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 92: Stasix - Product Status 59
  • Table 93: Stasix - Product Description 59
  • Table 94: Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 95: Flowable thrombin - Product Status 60
  • Table 96: Flowable thrombin - Product Description 60
  • Table 97: Next Gen Hemostat Kit - Product Status 61
  • Table 98: Next Gen Hemostat Kit - Product Description 61
  • Table 99: SURGIFLO - Sterile Field Preparation - Product Status 61
  • Table 100: SURGIFLO - Sterile Field Preparation - Product Description 62
  • Table 101: Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 102: GammaTF - Product Status 63
  • Table 103: GammaTF - Product Description 63
  • Table 104: gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 105: Hemogrip Spray-On Foam - Product Status 64
  • Table 106: Hemogrip Spray-On Foam - Product Description 64
  • Table 107: Vascular gel-e - External Wounds - Product Status 65
  • Table 108: Vascular gel-e - External Wounds - Product Description 65
  • Table 109: Vascular gel-e - Internal Surgical Use - Product Status 65
  • Table 110: Vascular gel-e - Internal Surgical Use - Product Description 65
  • Table 111: Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 112: HaemoPlax - Product Status 66
  • Table 113: HaemoPlax - Product Description 66
  • Table 114: PeproStat - Product Status 67
  • Table 115: PeproStat - Product Description 67
  • Table 116: Haemostatix Ltd - Ongoing Clinical Trials Overview 68
  • Table 117: PeproStat - A Controlled, Randomized, Multi-center, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeproStat in Intraoperative Surgical Haemostasis 69
  • Table 118: Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 119: ENT Hemostat - Product Status 70
  • Table 120: ENT Hemostat - Product Description 70
  • Table 121: Hemostatic Gel - Product Status 71
  • Table 122: Hemostatic Gel - Product Description 71
  • Table 123: KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 124: Keratin-Based Hemostat - Product Status 72
  • Table 125: Keratin-Based Hemostat - Product Description 72
  • Table 126: LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 127: Absorbable Hemostats - Product Status 73
  • Table 128: Absorbable Hemostats - Product Description 73
  • Table 129: LifePatch Heavy - Product Status 74
  • Table 130: LifePatch Heavy - Product Description 74
  • Table 131: LifePatch Surgery - Product Status 74
  • Table 132: LifePatch Surgery - Product Description 75
  • Table 133: Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 134: Antibiotic Hemostat - Product Status 76
  • Table 135: Antibiotic Hemostat - Product Description 76
  • Table 136: GENTA-COLL Resorb - Product Status 77
  • Table 137: GENTA-COLL Resorb - Product Description 77
  • Table 138: GENTA-FOIL Resorb - Product Status 77
  • Table 139: GENTA-FOIL Resorb - Product Description 78
  • Table 140: KOLLAGEN resorb - Product Status 78
  • Table 141: KOLLAGEN resorb - Product Description 78
  • Table 142: RESORBA CELL Fibrillar - Product Status 79
  • Table 143: RESORBA CELL Fibrillar - Product Description 79
  • Table 144: RESORBA CELL forte - Product Status 79
  • Table 145: RESORBA CELL forte - Product Description 80
  • Table 146: RESORBA CELL standard - Product Status 80
  • Table 147: RESORBA CELL standard - Product Description 80
  • Table 148: Rice University Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 149: KOD Hydrogel Hemostat - Product Status 81
  • Table 150: KOD Hydrogel Hemostat - Product Description 81
  • Table 151: Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 152: B6102 - Hemostat - Product Status 82
  • Table 153: B6102 - Hemostat - Product Description 82
  • Table 154: Sanofi Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 155: LeSeal - Product Status 83
  • Table 156: LeSeal - Product Description 83
  • Table 157: Lumagel - Product Status 84
  • Table 158: Lumagel - Product Description 84
  • Table 159: Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 85
  • Table 160: SEA-STAT - Product Status 85
  • Table 161: SEA-STAT - Product Description 85
  • Table 162: St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 86
  • Table 163: SURGICLOT - Product Status 86
  • Table 164: SURGICLOT - Product Description 86
  • Table 165: WRAPCLOT - Product Status 87
  • Table 166: WRAPCLOT - Product Description 87
  • Table 167: The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88
  • Table 168: Fibropad Patch - Product Status 88
  • Table 169: Fibropad Patch - Product Description 88
  • Table 170: Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 89
  • Table 171: Therus Acoustic Hemostasis System - Product Status 89
  • Table 172: Therus Acoustic Hemostasis System - Product Description 89
  • Table 173: Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 90
  • Table 174: Next Generation TT-173 - Product Status 90
  • Table 175: Next Generation TT-173 - Product Description 90
  • Table 176: TT-173 - Product Status 91
  • Table 177: TT-173 - Product Description 91
  • Table 178: United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 92
  • Table 179: HemoStyp General Surgeries Gauze - Product Status 92
  • Table 180: HemoStyp General Surgeries Gauze - Product Description 92
  • Table 181: HemoStyp Internal And External Procedure Gauze - Product Status 93
  • Table 182: HemoStyp Internal And External Procedure Gauze - Product Description 93
  • Table 183: HemoStyp Trauma Gauze - Product Status 93
  • Table 184: HemoStyp Trauma Gauze - Product Description 94
  • Table 185: University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 95
  • Table 186: Bleeding Controlling Device - Product Status 95
  • Table 187: Bleeding Controlling Device - Product Description 95
  • Table 188: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 96
  • Table 189: BioHemostat - Product Status 96
  • Table 190: BioHemostat - Product Description 96
  • Table 191: Wound Management Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 97
  • Table 192: HemaQuell - Product Status 97
  • Table 193: HemaQuell - Product Description 97
  • Table 194: Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 98
  • Table 195: Xcede - Femoral Artery - Product Status 98
  • Table 196: Xcede - Femoral Artery - Product Description 98
  • Table 197: Xcede - Laparoscopic Surgery - Product Status 99
  • Table 198: Xcede - Laparoscopic Surgery - Product Description 99
  • Table 199: Xcede - Vascular Surgery - Product Status 99
  • Table 200: Xcede - Vascular Surgery - Product Description 100
  • Table 201: Xcede Hemostatic Patch - Product Status 100
  • Table 202: Xcede Hemostatic Patch - Product Description 100
  • Table 203: Glossary 234

List of Figures

1.2 List of Figures

  • Figure 1: Wound Closure Hemostats - Pipeline Products by Stage of Development 13
  • Figure 2: Wound Closure Hemostats - Pipeline Products by Segment 14
  • Figure 3: Wound Closure Hemostats - Pipeline Products by Territory 15
  • Figure 4: Wound Closure Hemostats - Pipeline Products by Regulatory Path 16
  • Figure 5: Wound Closure Hemostats - Pipeline Products by Estimated Approval Date 17
  • Figure 6: Wound Closure Hemostats - Ongoing Clinical Trials 18
Back to Top